LAWSUITS NEWS & LEGAL INFORMATION
Amgen to Pay Ortho Biotech $200 Million in Antitrust Settlement
Amgen has reached an agreement to settle its outstanding antitrust litigation with Ortho Biotech Products.
Under terms of the agreement, Amgen will pay Ortho Biotech $200 million and the pending litigation in New Jersey District Court will be dismissed with prejudice. Amgen continues to deny that its challenged conduct was unlawful, and admits to no wrongdoing as part of the settlement agreement.
Ortho Biotech, a subsidiary of Johnson & Johnson, had alleged that discounts offered to oncology clinics on Amgen's Neupogen and Neulasta and Aranesp products violated antitrust laws.
Published on Jul-15-08
Under terms of the agreement, Amgen will pay Ortho Biotech $200 million and the pending litigation in New Jersey District Court will be dismissed with prejudice. Amgen continues to deny that its challenged conduct was unlawful, and admits to no wrongdoing as part of the settlement agreement.
Ortho Biotech, a subsidiary of Johnson & Johnson, had alleged that discounts offered to oncology clinics on Amgen's Neupogen and Neulasta and Aranesp products violated antitrust laws.
Legal Help
If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.Published on Jul-15-08
